At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
brentuximab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin for CD30 Positive Primary Mediastinal Large B-cell Lymphoma and 2 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6 cycles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionAug 2017
Study CompletionJan 2019
TodayJul 2026
First PostedNov 26, 2013
Enrollment StartNov 1, 2013
Primary CompletionAug 1, 2017
Study CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.6 years ago
Interventions
brentuximab vedotindrug
Trade name: Adcetris